Rucker, J. J. H. (2015). “Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential”. BMJ350 (may26 20): h2902–h2902. doi:10.1136/bmj.h2902. PMID26014506.
Vollenweider, Franz X.; Kometer, Michael (2010). “The neurobiology of psychedelic drugs: implications for the treatment of mood disorders”. Nature Reviews Neuroscience11 (9): 642–651. doi:10.1038/nrn2884. PMID20717121.
Griffiths, R. R.; Richards, W. A.; McCann, U.; et al. (2006). “Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance”. Psychopharmacology187 (3): 268–283. doi:10.1007/s00213-006-0457-5. PMID16826400.
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ (2021-4). “Trial of Psilocybin versus Escitalopram for Depression”. N Engl J Med384 (15): 1402–1411. doi:10.1056/NEJMoa2032994. PMID33852780.
Pellegrini, Manuela; Rotolo, Maria Concetta; Marchei, Emilia; et al. (2013). “Magic truffles or Philosopher's stones: a legal way to sell psilocybin?”. Drug Testing and Analysis5 (3): 182–185. doi:10.1002/dta.1400. PMID22887928.
Schmull, Michaela; Dal-Forno, Manuela; Lücking, Robert; Cao, Shugeng; Clardy, Jon; Lawrey, James D (2014). “Dictyonema huaorani(Agaricales: Hygrophoraceae), a new lichenized basidiomycete from Amazonian Ecuador with presumed hallucinogenic properties”. The Bryologist117 (4): 386–394. doi:10.1639/0007-2745-117.4.386. ISSN0007-2745.
Rucker, J. J. H. (2015). “Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential”. BMJ350 (may26 20): h2902–h2902. doi:10.1136/bmj.h2902. PMID26014506.
Vollenweider, Franz X.; Kometer, Michael (2010). “The neurobiology of psychedelic drugs: implications for the treatment of mood disorders”. Nature Reviews Neuroscience11 (9): 642–651. doi:10.1038/nrn2884. PMID20717121.
Griffiths, R. R.; Richards, W. A.; McCann, U.; et al. (2006). “Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance”. Psychopharmacology187 (3): 268–283. doi:10.1007/s00213-006-0457-5. PMID16826400.
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ (2021-4). “Trial of Psilocybin versus Escitalopram for Depression”. N Engl J Med384 (15): 1402–1411. doi:10.1056/NEJMoa2032994. PMID33852780.
Pellegrini, Manuela; Rotolo, Maria Concetta; Marchei, Emilia; et al. (2013). “Magic truffles or Philosopher's stones: a legal way to sell psilocybin?”. Drug Testing and Analysis5 (3): 182–185. doi:10.1002/dta.1400. PMID22887928.
Schmull, Michaela; Dal-Forno, Manuela; Lücking, Robert; Cao, Shugeng; Clardy, Jon; Lawrey, James D (2014). “Dictyonema huaorani(Agaricales: Hygrophoraceae), a new lichenized basidiomycete from Amazonian Ecuador with presumed hallucinogenic properties”. The Bryologist117 (4): 386–394. doi:10.1639/0007-2745-117.4.386. ISSN0007-2745.